Thyroid cancer cases remained rare and did not appear significantly higher compared with placebo groups
If semaglutide isn't delivering expected results after 812 weeks, PlexusDx practitioners can transition you to tirzepatide (a dual GIP/GLP-1 agonist) or GLP-Squared, the dual-compound formulation combining both agents
We successfully recruited four individuals for each group, adhering to the established inclusion and exclusion criteria previously used for proteomic analysis recruitment
Gastroesophageal reflux disease (GERD) causes up to 25% of chronic sore throats, often worse in the morning due to overnight acid exposure while lying flat
Olave FA, Aguayo FI, Roman-Albasini L, Corrales WA, Silva JP, Gonzalez PI, et al
GIP Glucose-Dependent Insulinotropic Polypeptide Incretin K (K-cell) (Duodenum) GLP-1 GLP-1 receptor GIP receptor 2 GLP-1 2 GLP-1 (Glucagon-like Peptide-1) GIP (Glucose-dependent Insulinotropic Polypeptide) Mounjaro (Tirzepatide) GLP-1 GIP Mounjaro (Tirzepatide) GLP-1 GIP Dual GIP/GLP-1 Receptor Agonist : : SURMOUNT-1 tirzepatide semaglutide SURMOUNT-5 tirzepatide semaglutide 47% (Rubino et al., 2026, NEJM) : 3 (Triple agonist : GLP-1, GIP, Glucagon) Retatrutide 3 FAQ GLP-1 GIP GLP-1/GIP
